Eledon Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited; amounts below are in U.S. dollars.
Business context
Eledon is a clinical-stage biotechnology company with no approved products and no product-sales revenue. Its lead candidate, tegoprubart, targets the CD40L pathway and is being developed principally for kidney transplantation, with potential applications including ALS. The company reported a strategic shift in January 2023 to prioritize kidney-transplant programs, discontinue islet-cell transplantation, and deprioritize IgA nephropathy (IgAN). It said IgAN clinical activities and related spending would end in Q4 2023.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $7.9 million | $7.5 million | $23.2 million | $19.8 million |
| General and administrative expense | $3.3 million | $3.1 million | $9.4 million | $9.9 million |
| Total operating expenses | $11.2 million | $10.6 million | $32.7 million | $29.7 million |
| Net loss | $10.3 million | $10.5 million | $30.7 million | $29.6 million |
| Net loss per share, basic and diluted | $0.35 | $0.73 | $1.35 | $2.07 |
Margins are not meaningful because Eledon had no product revenue. Q3 net loss narrowed by $0.1 million year over year, while nine-month net loss widened by $1.1 million. Nine-month R&D expense rose $3.4 million, mainly from clinical-trial and clinical-material costs; G&A fell $0.5 million. Higher interest income increased other income to $2.0 million for the nine months, versus $0.2 million in 2022.
- Cash and liquidity: At September 30, cash and cash equivalents were $3.7 million and short-term investments were $55.9 million, or $59.6 million combined, versus $56.4 million in cash and no short-term investments at December 31, 2022. Working capital was $60.1 million.
- Cash flow: Nine-month operating cash use was $30.4 million, investing cash use was $55.4 million (primarily purchases of short-term investments), and financing provided $33.0 million. Cash and cash equivalents declined $52.7 million; much of the cash decrease reflects purchases of investments, not equivalent operating burn.
- Debt and liabilities: The filing reports no outstanding debt or credit facility. Total liabilities were $4.7 million, including $2.9 million current liabilities, at September 30.
- Equity and dilution: The May 2023 private placement generated $35.0 million gross and approximately $33.0 million net proceeds. Common shares outstanding were 23.5 million at September 30; substantial warrants and potential tranche issuances create further dilution risk.
Clinical progress, outlook, and material risks
- The Phase 2 BESTOW kidney-transplant study dosed its first participant in August 2023 and is planned to enroll 120 participants. The Phase 1b study’s first participant was dosed in July 2022. The filing, signed in November, also describes a November 2023 interim update from 11 Phase 1b participants: tegoprubart was reported generally well tolerated, with one mild rejection episode and no graft losses or deaths. These are interim findings, not proof of efficacy.
- Management reported that continued ALS clinical development requires financing specifically for that program; available liquidity was not sufficient to fund it. No assurance was given that financing would be available on acceptable terms.
- The company may receive up to a further $105 million in second and third private-placement closings, subject to clinical milestones and share-price/trading conditions, and up to $45.5 million if all initial-closing common warrants are exercised. These amounts are contingent and are not assured sources of liquidity.
- Management and the filing state there is substantial doubt about Eledon’s ability to continue as a going concern. The company expects continuing losses and says it will need additional capital; failure to obtain it could require major curtailment, a change in strategy, or cessation of operations. No specific cash-runway estimate or numerical financial guidance is provided.
- Key risks include clinical and regulatory failure or delay, financing availability and dilution, dependence on contract manufacturers and research organizations, competition, and macroeconomic and capital-market volatility. The filing reports no material legal proceedings and no contingent liabilities requiring accrual at September 30.
- Subsequent event: 653,000 pre-funded warrants were exercised in November 2023, and the corresponding common shares were issued.
Important facts for investors to verify
- Whether clinical and trading conditions for the additional private-placement tranches are met, and whether warrants are exercised.
- Cash burn, investment maturities, and updated liquidity/runway disclosures in subsequent filings, given the going-concern warning.
- Enrollment, safety, rejection, kidney-function, and follow-up data from BESTOW and the Phase 1b kidney-transplant program.
- Whether dedicated ALS financing is obtained and what clinical-development plans follow.
- Actual dilution from outstanding warrants, equity awards, and any additional financing.